ClinicalTrials.gg
RecruitingNCT07466160Updated Mar 12, 2026

A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors

A Phase 1/2 interventional study of 7MW3711 and JS207 in Solid Tumor, sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
280
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study was designed to evaluate the efficacy and safety of 7MW3711 in combination with JS207 in subjects with solid tumor.

Read the detailed description

A Multi-center, Open-label, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of 7MW3711 in Combination With JS207 with or without Chemotheray in Patients With Advanced Solid Tumors.

02

Conditions studied

  • Solid Tumor

Keywords

  • NSCLC
  • SCLC
03

In context

Lead sponsor

Mabwell (Shanghai) Bioscience Co., Ltd. is the lead sponsor of 54 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (ECOG) performance status of 0 to 1.
  2. of at least 3 months as assessed by the Investigator.
  3. Phase 1b: or cytologically confirmed locally advanced or solid tumor, progressive after last treatment received and who progressed on or after standard therapies or intolerant to approved therapies or who lack of effient standard therapies. Phase 2: Histologically or cytologically confirmed locally advanced or metastatic selected advanced solid tumors.
  4. Measurable or evaluable disease by v1.1.
  5. Have adequate hematopoietic, renal and hepatic functions.
  6. Men or women willing to use adequate measures throughout the study.

Exclusion criteria

Exclusion Criteria:

  1. Have other prior within 3 years before the first administration.
  2. Known central nervous system disease or carcinomatous meningitis except for treated and stable .
  3. Have significant, uncontrolled, or active cardiovascular disease.
  4. Known history of , or intestinal lung disease, or other respiratory diseases requring inpatient treatments within 4 weeks prior to first administration.
  5. Have adverse events due to prior antitumor therapy not resolved to grade 1 or lower by V6.0.
  6. Have active infections requiring treatment within 14 weeks; have infection of , active infection of and .
  7. Prior treatment with an antibody drug conjugate (ADC) that consists of an topoisomerase I inhibitor.
  8. Prior treatment with B7-H3 targeted agents.
  9. Have received any other drugs or medical device within 4 weeks prior to the first administration.
  10. Pregnant, or nursing females.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    Phase 1b: Safety run-in

    Multiple dose levels of 7MW3711 will be explored in combination with JS207 with or without Chemotheray administered intravenously (IV) at a fixed dose as specified in the protocol.

    Drug: 7MW3711 · Drug: JS207 · Drug: Cisplatin · Drug: Carboplatin

  • Experimental
    Phase 2: Dose expansion

    7MW3711 will be administered at the selected RDE in combination with JS207 with or without Chemotheray administered IV at a fixed dose as specified in the protocol.

    Drug: 7MW3711 · Drug: JS207 · Drug: Cisplatin · Drug: Carboplatin

Interventions

  • Drug7MW3711

    7MW3711 will be administered as IV infusion.

  • DrugJS207

    JS207 will be administered as IV infusion.

  • Cisplatin will be administered as IV infusion.

  • Carboplatin will be administered as IV infusion.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs)

    AEs are assessed based on NCI CTCAE v6.0.

    Time frame: Up to approximately 2 years

  2. Maximum tolerate dose(MTD)

    MTD of 7MW3711

    Time frame: Up to approximately 2 years

  3. Recommended Expansion Dose (RED)

    RED of 7MW3711

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Area Under the Concentration-time Curve (AUC)

    AUC of 7MW3711

    Time frame: Up to approximately 2 years

  2. Maximum concentration (Cmax)

    Cmax of 7MW3711

    Time frame: Up to approximately 2 years

  3. Plasma clearance (CL)

    CL of 7MW3711

    Time frame: Up to approximately 2 years

  4. Half-life (t1/2)

    t1/2 of 7MW3711

    Time frame: Up to approximately 2 years

  5. Time to peak drug concentration (Tmax)

    Tmax of 7MW3711

    Time frame: Up to approximately 2 years

  6. Investigator-assessed progression-free survival (PFS)

    PFS defined as the time interval from the first study drug administration to the first documented PD or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years

  7. Overall survival (OS)

    OS defined as the time interval from the first study drug administration to death due to any cause.

    Time frame: Up to approximately 2 years

  8. Investigator-assessed disease control rate (DCR)

    DCR defined as the proportion of subjects with a BOR of CR, PR, or stable disease (SD).

    Time frame: Up to approximately 2 years

  9. Immunogenicity

    Incidence and rates of ADA

    Time frame: Up to approximately 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2026
First posted
Mar 12, 2026
StartActual
Feb 11, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2029
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07466160
Responsible party
Sponsor
First posted
Mar 12, 2026
Start date
Feb 11, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Mar 12, 2026

Study contacts

Shun Lu, Doctor
Contact
shun_lu@hotmail.com
021-22200000 ext. 3121

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/Anti-VEGF Bispecific Antibody JS207

Start the discussion